-DOCSTART- -X- O
BACKGROUND -X- _ O
: -X- _ O
Mother-to-child -X- _ O
transmission -X- _ O
( -X- _ O
MTCT -X- _ O
) -X- _ O
is -X- _ O
the -X- _ O
main -X- _ O
cause -X- _ O
of -X- _ O
HIV-1 -X- _ B-Patient
infection -X- _ I-Patient
in -X- _ O
children -X- _ O
worldwide. -X- _ O
Given -X- _ O
that -X- _ O
the -X- _ O
C-type -X- _ B-Intervention
lectin -X- _ I-Intervention
receptor -X- _ I-Intervention
, -X- _ I-Intervention
dendritic -X- _ I-Intervention
cell-specific -X- _ I-Intervention
ICAM-grabbing -X- _ I-Intervention
non-integrin-related -X- _ I-Intervention
( -X- _ I-Intervention
DC-SIGNR -X- _ I-Intervention
, -X- _ I-Intervention
also -X- _ I-Intervention
known -X- _ I-Intervention
as -X- _ I-Intervention
CD209L -X- _ I-Intervention
or -X- _ I-Intervention
liver -X- _ I-Intervention
/ -X- _ I-Intervention
lymph -X- _ I-Intervention
nodeâ€“specific -X- _ I-Intervention
ICAM- -X- _ I-Intervention
grabbing -X- _ I-Intervention
non-integrin -X- _ I-Intervention
( -X- _ I-Intervention
L-SIGN -X- _ I-Intervention
) -X- _ I-Intervention
) -X- _ I-Intervention
, -X- _ O
can -X- _ O
interact -X- _ O
with -X- _ O
pathogens -X- _ O
including -X- _ O
HIV-1 -X- _ B-Patient
and -X- _ O
is -X- _ O
expressed -X- _ O
at -X- _ O
the -X- _ O
maternal-fetal -X- _ O
interface -X- _ O
, -X- _ O
we -X- _ O
hypothesized -X- _ O
that -X- _ O
it -X- _ O
could -X- _ O
influence -X- _ O
MTCT -X- _ O
of -X- _ O
HIV-1. -X- _ O
METHODS -X- _ O
AND -X- _ O
FINDINGS -X- _ O
: -X- _ O
To -X- _ O
investigate -X- _ O
the -X- _ O
potential -X- _ O
role -X- _ O
of -X- _ O
DC-SIGNR -X- _ B-Intervention
in -X- _ O
MTCT -X- _ B-Patient
of -X- _ I-Patient
HIV-1 -X- _ I-Patient
, -X- _ O
we -X- _ O
carried -X- _ O
out -X- _ O
a -X- _ O
genetic -X- _ O
association -X- _ O
study -X- _ O
of -X- _ O
DC-SIGNR -X- _ B-Intervention
in -X- _ O
a -X- _ O
well-characterized -X- _ O
cohort -X- _ O
of -X- _ O
197 -X- _ B-Patient
HIV-infected -X- _ I-Patient
mothers -X- _ I-Patient
and -X- _ I-Patient
their -X- _ I-Patient
infants -X- _ I-Patient
recruited -X- _ O
in -X- _ O
Harare -X- _ O
, -X- _ O
Zimbabwe. -X- _ O
Infants -X- _ B-Outcome
harbouring -X- _ I-Outcome
two -X- _ I-Outcome
copies -X- _ I-Outcome
of -X- _ I-Outcome
DC- -X- _ I-Outcome
SIGNR -X- _ I-Outcome
H1 -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
H3 -X- _ I-Outcome
haplotypes -X- _ I-Outcome
( -X- _ I-Outcome
H1-H1 -X- _ I-Outcome
, -X- _ I-Outcome
H1-H3 -X- _ I-Outcome
, -X- _ I-Outcome
H3-H3 -X- _ I-Outcome
) -X- _ I-Outcome
had -X- _ I-Outcome
a -X- _ I-Outcome
3.6-fold -X- _ I-Outcome
increased -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
in -X- _ I-Outcome
utero -X- _ I-Outcome
( -X- _ I-Outcome
IU -X- _ I-Outcome
) -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.013 -X- _ I-Outcome
) -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
infection -X- _ I-Outcome
and -X- _ I-Outcome
a -X- _ I-Outcome
5.7-fold -X- _ I-Outcome
increased -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
intrapartum -X- _ I-Outcome
( -X- _ I-Outcome
IP -X- _ I-Outcome
) -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.025 -X- _ I-Outcome
) -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
infection -X- _ I-Outcome
after -X- _ O
adjusting -X- _ O
for -X- _ O
a -X- _ O
number -X- _ O
of -X- _ O
maternal -X- _ O
factors. -X- _ O
The -X- _ O
implicated -X- _ O
H1 -X- _ O
and -X- _ O
H3 -X- _ O
haplotypes -X- _ O
share -X- _ O
two -X- _ O
single -X- _ O
nucleotide -X- _ O
polymorphisms -X- _ O
( -X- _ O
SNPs -X- _ O
) -X- _ O
in -X- _ O
promoter -X- _ O
region -X- _ O
( -X- _ O
p-198A -X- _ O
) -X- _ O
and -X- _ O
intron -X- _ O
2 -X- _ O
( -X- _ O
int2-180A -X- _ O
) -X- _ O
that -X- _ O
were -X- _ O
associated -X- _ B-Outcome
with -X- _ I-Outcome
increased -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
both -X- _ I-Outcome
IU -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.045 -X- _ I-Outcome
and -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.003 -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
and -X- _ I-Outcome
IP -X- _ I-Outcome
( -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.025 -X- _ I-Outcome
, -X- _ I-Outcome
for -X- _ I-Outcome
int2-180A -X- _ I-Outcome
) -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
infection. -X- _ I-Outcome
The -X- _ O
promoter -X- _ O
variant -X- _ O
reduced -X- _ O
transcriptional -X- _ O
activity -X- _ O
in -X- _ O
vitro. -X- _ O
In -X- _ O
homozygous -X- _ O
H1 -X- _ O
infants -X- _ O
bearing -X- _ O
both -X- _ O
the -X- _ O
p-198A -X- _ O
and -X- _ O
int2-180A -X- _ O
mutations -X- _ O
, -X- _ O
we -X- _ O
observed -X- _ O
a -X- _ O
4-fold -X- _ O
decrease -X- _ O
in -X- _ O
the -X- _ O
level -X- _ O
of -X- _ O
placental -X- _ O
DC-SIGNR -X- _ O
transcripts -X- _ O
, -X- _ O
disproportionately -X- _ O
affecting -X- _ O
the -X- _ O
expression -X- _ O
of -X- _ O
membrane-bound -X- _ O
isoforms -X- _ O
compared -X- _ O
to -X- _ O
infant -X- _ O
noncarriers -X- _ O
( -X- _ O
P -X- _ O
= -X- _ O
0.011 -X- _ O
) -X- _ O
. -X- _ O
CONCLUSION -X- _ O
: -X- _ O
These -X- _ O
results -X- _ O
suggest -X- _ O
that -X- _ O
DC-SIGNR -X- _ B-Outcome
plays -X- _ I-Outcome
a -X- _ I-Outcome
crucial -X- _ I-Outcome
role -X- _ I-Outcome
in -X- _ I-Outcome
MTCT -X- _ I-Outcome
of -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
and -X- _ I-Outcome
that -X- _ I-Outcome
impaired -X- _ I-Outcome
placental -X- _ I-Outcome
DC-SIGNR -X- _ I-Outcome
expression -X- _ I-Outcome
increases -X- _ I-Outcome
risk -X- _ I-Outcome
of -X- _ I-Outcome
transmission -X- _ I-Outcome
. -X- _ O

